In the phase II DESTINY-Lung01 trial, they enrolled previously treated patients with unresectable or metastatic NSCLC and HER2 overexpression (cohort 1, n = 90, divided into 1 and 1A according to drug dose of 6.4 mg/kg or 5.4 mg/kg) or HER2 mutations (cohort 2, n = 91). Here, ERBB2 is linked to non-small cell lung carcinoma.